Metagenomi Q1 net loss $25.1M, cash $327.4M; regains base editing and RIGS rights from Moderna

Metagenomi Therapeutics, Inc.

2024-Q1 EPS reported -$1.19 revenue$11,159,000

Q1 net loss $25.1M ($1.19/share) vs $16.1M loss in Q1 2023; collaboration revenue $11.2M.
Cash, equivalents and marketable securities $327.4M including $80.7M net IPO proceeds; runway into 2027.
Regained full global rights to wholly-owned base editors and RIGS; terminated PH1 collaboration with Moderna.
Hemophilia A program: development candidate nomination expected mid-2024; 12-month NHP durability data in 2H 2024.
R&D expenses $31.4M (+56% YoY); base editors expanded genome targetability 5-fold vs SpCas9.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Metagenomi Therapeutics, Inc. reported quarter ended March 31, 2024 results: revenue $11,159 thousand, net income Net loss of $(25,148) thousand, EPS $(1.19) per share.

Period: quarter ended March 31, 2024
Revenue: $11,159 thousand
Net income: Net loss of $(25,148) thousand
EPS: $(1.19) per share
Result: reported results

Exact text from the filing

announced its financial results for the quarter ended March 31, 2024

View on SEC.gov

Browse all earnings releases →

Metagenomi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-059532

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.